Vesalius Biocapital III, the Strassen, Luxembourg-based specialist life sciences venture capital investor, closed the VBC III fund, securing €120m of equity commitments.
This includes commitments of €30 million from the European Investment Fund (EIF) and new and existing investors from Europe, the Americas and MENA.
Vesalius Biocapital III targets later-stage European life science companies in drug development, medtech, diagnostics and digital health with the goal of investing in 10-15 companies over the lifetime of the fund.
The fund has executed three investments to date. These include:
– Forendo, a clinical stage drug development company focusing on novel treatments in women’s health;
– Mecuris, a Munich-based medtech developing an online platform for customizable and 3D-printed orthotics and prosthetics; and
– SWORD Health, a tech-enabled provider of physical therapy, pairing its AI-powered digital therapists with human clinical teams to recover patients.
Led by Dr Christian Schneider and Stéphane Verdood, Vesalius Biocapital III is a specialist life sciences venture capital fund and is in line with predecessor funds Vesalius Biocapital I and Vesalius Biocapital II, which have supported life sciences companies since 2007. Vesalius Biocapital I and II raised over €150m and contributed in the development of over 20 companies.
The investment portfolio is balanced between drug development, medical device & diagnostics and digital health investments and committed to providing capital to science-backed innovation and ambitious entrepreneurs, with a focus on exit within five years.